Jun 1, 2016 1 min read

CANONSBURG — Mylan N.V. on Wednesday announced the U.S. launch of a generic version of Cephalon’s Nuvigil, used to improve wakefulness in adults with sleep apnea.

Southpointe-based Mylan received final approval from the U.S. Food and Drug Administration for its Armodafinil tablets in 50-, 150-, and 250 mg doses. The medicine is used to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, narcolepsy or shift-work disorder.

Nuvigil had U.S. sales of approximately $489.7 million for the 12 months ending March 31, 2016, according to IMS Health.